Laser Trabeculoplasty: A Whole New Approach To Managing Patients With Primary Open Angle Glaucoma (POAG)

The results of the Glaucoma Laser Trial (GLT) are encouraging regarding the usefulness of Laser Trabeculoplasty (LT) as an initial treatment for POAG. It appears that LT is at least as good if not better than starting with medications, because in the short term, LT provides good pressure control and has the advantage of postponing and/or reducing the inconvenience, nuisance, and side effects associated with taking medications.

The pressure-lowering effects of laser trabeculoplasty in Glaucoma Laser Trial (GLT) patients with high Intraocular Pressure (IOP) and not controlled by medicines encourages more frequent use of laser trabeculoplasty.
Evidence of the GLT suggests that, within the 2-year follow-up of the trial, Laser Trabeculoplasty is both effective and safe.

Selective Laser Trabeculoplasty - SLT

 Glaucoma is a disease in which increased pressure in the eye causes permanent damage to the Optic nerve. If this process is not treated this will lead to complete blindness.

There are several options for treating Glaucoma: various types of drops, laser treatments, and surgery.

In the past, the only available laser treatment involved burning a hole in the drainage system (trabecular meshwork). Although effective, this procedure causes significant damage to the meshwork.

Now an exciting new technology allows treatment of the meshwork without damage. Using this low powered laser we selectively clear the pigment cells, which clog the meshwork. The intraocular fluid can then drain freely, reducing the pressure in the eye.

The pressure lowering effect of SLT often takes several months to reach its full potential. And because there is no damage to the meshwork, this procedure can be repeated for additional pressure lowering effect when needed.

While some of our patients have been able to discontinue the use of drops, we cannot promise that you will have the same results. However, Dr. Bogart does feel that this new technology offers real help and hope to his Glaucoma patients.

The Selective Trabeculoplasty Advantage

Preclinical studies show that SLT does not cause the coagulative damage to the trabecular meshwork caused by Argon Laser Trabeculoplasty (ALT) as shown in Example A above.

SLT selectively targets pigmented trabecular meshwork cells, conserving surrounding non-pigmented cells.

This procedure is SAFE and is NOT associated with any systemic adverse side effects.

Stratus Oct

What is it?
A direct cross-sectional imaging that allows the doctor to analyze layers of the retina and optic nerve; measuring and monitoring delicate structures and any changes within these structures.

Why is it used?
There are TWO possible reasons for your doctor to order this procedure:
  • Early detection of glaucoma OR
  • Monitoring the effectiveness of current therapies in arresting the effects of the disease of glaucoma on your vision.
Does it replace a visual field?
No, it does not. A visual field evaluates your level of visual function. However, the structural damage from glaucoma occurs up to FIVE years PRIOR to the patient experiencing VISION loss. With HRT a personalized visual map of your retina and optic nerve is compared (by computer technology) to the new scan, and any changes are highlighted. Your doctor can immediately see if your glaucoma is progressing and then prescribe needed therapies, BEFORE vision loss is experienced.
Share by: